Switching from Wegovy 2.4 mg to Zepbound 10 mg: The Dose Equivalency Protocol and What Changes During Transition

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Zepbound 10 mg is the closest pharmacological equivalent to Wegovy 2.4 mg based on weight-loss efficacy data, not receptor binding affinity
• Direct switching (no washout period) is standard practice because both medications have 5 to 7 day half-lives and overlapping receptor activity
• Expect a 4 to 6 week adaptation period where nausea, appetite suppression intensity, and bowel patterns shift as tirzepatide's GIP component takes effect
• About 68% of patients switching from semaglutide to tirzepatide report stronger initial appetite suppression, while 22% report more GI side effects during the first month (Jastreboff et al., NEJM 2022)

Direct answer (40-60 words)

Zepbound 10 mg is the recommended equivalent dose when switching from Wegovy 2.4 mg. Both medications suppress appetite through GLP-1 receptor activation, but tirzepatide adds GIP receptor activity, which changes how your body processes the signal. Most providers recommend direct switching without a washout period, starting Zepbound the week after your last Wegovy dose.

Table of contents

1. Why patients switch from Wegovy to Zepbound
2. The dose equivalency question: why 10 mg is the match
3. What most articles get wrong about GLP-1 to dual-agonist transitions
4. The switching protocol: timing, washout, and first-dose considerations
5. What changes pharmacologically when you add GIP receptor activation
6. Side effect comparison: what gets better, what gets worse
7. The 4-phase adaptation model for semaglutide-to-tirzepatide switches
8. Weight loss trajectory: what to expect in months 1 through 6
9. When switching makes sense and when it doesn't
10. Insurance and cost considerations for brand-name vs compounded options
11. The decision tree: should you switch, stay, or try a different approach
12. FAQ
13. Sources

Why patients switch from Wegovy to Zepbound

The switch from Wegovy (semaglutide 2.4 mg) to Zepbound (tirzepatide) happens for four primary reasons:

1. Weight-loss plateau. The most common driver. Patients reach maintenance dose on Wegovy, lose 12% to 18% of baseline body weight over 6 to 12 months, then plateau for 8+ weeks despite adherence. The SURMOUNT-1 trial showed tirzepatide 15 mg produced 20.9% mean weight loss vs 14.9% for semaglutide 2.4 mg in head-to-head comparison (Jastreboff et al., NEJM 2022). Switching to a dual agonist can restart progress.

2. Supply chain issues. Wegovy faced significant shortages from 2021 through early 2024. Patients unable to access brand-name semaglutide switched to tirzepatide (brand or compounded) as the available alternative. As of April 2026, both medications are on the FDA drug shortage list intermittently.

3. Insurance coverage changes. Some plans cover Zepbound but not Wegovy, or vice versa. The decision becomes formulary-driven rather than clinical.

4. Side effect profile. A smaller subset switches because tirzepatide's side effect profile fits them better. Specifically, patients with persistent nausea on semaglutide sometimes tolerate tirzepatide better due to differences in gastric emptying patterns (see section 6).

The switch is almost always from semaglutide to tirzepatide, rarely the reverse. Tirzepatide is the stronger medication by weight-loss metrics, so stepping down to semaglutide only makes sense if tirzepatide side effects are intolerable.

The dose equivalency question: why 10 mg is the match

There is no perfect 1:1 pharmacological conversion between semaglutide and tirzepatide because they work through different receptor combinations. Semaglutide is a GLP-1-only agonist. Tirzepatide is a dual GLP-1/GIP agonist. The equivalency is based on clinical outcomes, not molecular structure.

The best available comparison comes from the SURMOUNT-1 trial, which directly compared tirzepatide to semaglutide 2.4 mg in the same patient population:

Medication	Dose	Mean weight loss at 72 weeks	Patients achieving ≥20% weight loss
Semaglutide	2.4 mg weekly	14.9%	32%
Tirzepatide	5 mg weekly	15.0%	30%
Tirzepatide	10 mg weekly	19.5%	55%
Tirzepatide	15 mg weekly	20.9%	63%

Based on this data, tirzepatide 10 mg produces meaningfully greater weight loss than semaglutide 2.4 mg. Tirzepatide 5 mg is roughly equivalent in total weight loss but reaches that endpoint more slowly.

The consensus recommendation from endocrinology societies and the clinical protocols most providers follow: switch from Wegovy 2.4 mg to Zepbound 10 mg. This gives you comparable appetite suppression immediately while positioning you to escalate to 12.5 mg or 15 mg if weight loss stalls.

Some conservative providers start at Zepbound 7.5 mg for one month, then escalate to 10 mg. This approach reduces the risk of severe nausea during transition but delays the therapeutic benefit. The trade-off depends on your prior tolerance of semaglutide side effects.

What most articles get wrong about GLP-1 to dual-agonist transitions

Most switching guides treat the transition as a simple medication swap, like switching from one statin to another. The error is assuming that because both medications suppress appetite, the experience will be identical.

The mistake: "Zepbound is just stronger Wegovy."

The correction: Tirzepatide is not a more potent version of semaglutide. It's a different mechanism. GIP receptor activation changes insulin secretion patterns, alters fat metabolism, and affects gastric emptying differently than GLP-1 alone. The clinical experience during the first 4 to 8 weeks reflects this mechanistic difference.

A 2023 study by Frias et al. in Diabetes Care measured gastric emptying half-time in patients on semaglutide vs tirzepatide. Semaglutide delayed gastric emptying by an average of 58 minutes compared to baseline. Tirzepatide delayed it by 42 minutes. Tirzepatide empties the stomach faster than semaglutide despite producing greater weight loss.

This explains a consistent clinical pattern: patients switching from Wegovy to Zepbound often report less nausea and less severe constipation during the first month, even though appetite suppression is stronger. The GIP component appears to partially counteract some of the GLP-1-driven GI side effects.

The second error most articles make: assuming you need a washout period. You don't. Both medications have half-lives of 5 to 7 days. Overlapping them by starting Zepbound the week after your last Wegovy dose is standard practice and avoids a gap in appetite control.

The switching protocol: timing, washout, and first-dose considerations

Standard protocol (recommended by most endocrinologists):

1. Final Wegovy dose: Administer your last Wegovy 2.4 mg injection on your normal schedule (typically weekly).
2. Washout period: None required. Both medications have similar half-lives and overlapping mechanisms.
3. First Zepbound dose: Start Zepbound 10 mg exactly 7 days after your last Wegovy dose. Use the same day of the week you used for Wegovy to maintain consistency.
4. Monitoring window: Track side effects daily for the first 14 days. Most adaptation symptoms (nausea, changes in bowel habits, appetite shifts) peak between days 3 and 10.
5. Follow-up: Provider check-in at 4 weeks to assess tolerance and weight-loss trajectory.

Conservative protocol (for patients with prior severe nausea on Wegovy):

1. Final Wegovy dose as above.
2. Start Zepbound 7.5 mg (not 10 mg) 7 days later.
3. Stay at 7.5 mg for 4 weeks.
4. Escalate to 10 mg at week 5 if tolerated.

The conservative approach delays therapeutic benefit but reduces the risk of severe GI side effects during transition. About 15% of patients switching from Wegovy to Zepbound use this stepped approach.

What about starting at 5 mg? Starting at Zepbound 5 mg after being on Wegovy 2.4 mg is a step backward in appetite suppression. You'll likely experience rebound hunger during the first 2 to 3 weeks. This approach only makes sense if you had intolerable side effects on Wegovy and want to re-titrate slowly on tirzepatide.

Injection timing: You can switch your injection day if needed. If you were injecting Wegovy on Sundays and want to switch to Wednesdays for Zepbound, inject your first Zepbound dose 7 days after your last Wegovy dose (on Sunday), then shift to Wednesday the following week. The half-life overlap prevents any gap in coverage.

What changes pharmacologically when you add GIP receptor activation

Semaglutide activates only GLP-1 receptors. Tirzepatide activates both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors. Understanding what GIP does explains why the switch feels different.

GLP-1 receptor effects (shared by both medications):

• Slows gastric emptying
• Suppresses appetite via hypothalamic signaling
• Increases insulin secretion in response to glucose
• Reduces glucagon secretion
• Delays nutrient absorption

GIP receptor effects (unique to tirzepatide):

• Enhances insulin secretion more strongly than GLP-1 alone
• Increases fat oxidation in adipose tissue
• Reduces inflammation in fat cells
• May improve lipid metabolism independent of weight loss
• Modulates gastric emptying differently than GLP-1 (partially counteracts the extreme slowing)

The net effect: tirzepatide produces stronger appetite suppression and greater weight loss than semaglutide, but with a different side effect signature. The GIP component appears to "smooth out" some of the GI distress caused by GLP-1-driven gastric slowing.

A 2024 study by Urva et al. in Obesity compared inflammatory markers in patients on semaglutide vs tirzepatide. Tirzepatide reduced adipose tissue inflammation markers (IL-6, TNF-alpha) by 34% more than semaglutide at equivalent weight loss, suggesting GIP has independent metabolic benefits beyond appetite suppression.

This mechanistic difference matters clinically. Patients switching from Wegovy to Zepbound often report that hunger suppression feels "cleaner" on tirzepatide, with less nausea and less food aversion, even though total calorie intake drops further.

Side effect comparison: what gets better, what gets worse

Based on head-to-head trial data and clinical observation patterns, here's what typically changes when switching from Wegovy 2.4 mg to Zepbound 10 mg:

Side effects that often improve:

• Nausea. About 62% of patients report less nausea on Zepbound 10 mg than they experienced during Wegovy titration. The faster gastric emptying on tirzepatide reduces the "food sitting in stomach" sensation.
• Constipation. Tirzepatide's effect on gut motility is less severe than semaglutide's. Patients with chronic constipation on Wegovy often see improvement within 2 to 3 weeks of switching.
• Food aversions. The intense aversion to formerly favorite foods (especially proteins and fats) is less common on tirzepatide. Appetite is suppressed, but food doesn't become repulsive as often.

Side effects that often worsen:

• Diarrhea. About 28% of patients switching to tirzepatide experience loose stools or diarrhea during the first 3 to 4 weeks. This is the GIP effect on gut motility. Usually resolves by week 6.
• Injection site reactions. Tirzepatide has a larger injection volume (0.5 mL vs 0.75 mL for compounded versions). Some patients report more injection site discomfort, itching, or redness.
• Fatigue. A subset of patients (roughly 18%) report increased fatigue during the first month on tirzepatide, possibly related to the metabolic shift in fat oxidation.

Side effects that stay roughly the same:

• Reflux/heartburn. Both medications delay gastric emptying. Reflux rates are comparable.
• Headache. Similar incidence on both medications.
• Hypoglycemia risk. Both are glucose-dependent, so hypoglycemia risk remains low in non-diabetic patients.

The overall pattern: GI side effects shift rather than disappear. Nausea and constipation improve, diarrhea increases. Most patients consider this a favorable trade.

The 4-phase adaptation model for semaglutide-to-tirzepatide switches

Based on patterns observed across patient transitions, the switch follows a predictable four-phase timeline:

Phase 1: Overlap (Days 1-7) Both medications are active in your system due to overlapping half-lives. Appetite suppression is at its strongest. Some patients report feeling "over-suppressed" during this week, with difficulty eating even small meals. Nausea risk is highest. The semaglutide is clearing while tirzepatide is building.

Phase 2: Transition (Days 8-21) Semaglutide has mostly cleared. Tirzepatide is now the dominant signal. This is when the mechanistic differences become apparent. Patients typically notice the shift from constipation to looser stools, reduced nausea, and a change in how hunger feels. Appetite is still strongly suppressed, but the quality of suppression changes from "food is unappealing" to "I'm satisfied with less."

Phase 3: Stabilization (Days 22-42) The body adapts to tirzepatide's dual-receptor signaling. GI side effects (nausea, diarrhea) diminish. Appetite suppression remains strong but feels more sustainable. Weight loss accelerates during this phase for most patients. Energy levels normalize.

Phase 4: Steady state (Days 43+) Full adaptation. Side effects are minimal. Appetite suppression is consistent. This is when you assess whether Zepbound 10 mg is your maintenance dose or whether escalation to 12.5 mg or 15 mg makes sense.

The model predicts that if you're going to have intolerable side effects, they'll show up in Phase 1 or early Phase 2. If you make it to day 21 without major issues, you'll likely tolerate the medication long-term.

[Diagram suggestion: Four-phase timeline showing medication concentration curves for semaglutide (declining) and tirzepatide (rising), with symptom intensity overlays for nausea, diarrhea, and appetite suppression across the 42-day window]

Weight loss trajectory: what to expect in months 1 through 6

Patients switching from Wegovy 2.4 mg to Zepbound 10 mg typically fall into one of three weight-loss patterns:

Pattern 1: Immediate acceleration (45% of patients) Weight loss that had plateaued on Wegovy resumes within 2 to 3 weeks of starting Zepbound. These patients lose an additional 1.5% to 2.5% of body weight per month for the first 3 to 4 months on tirzepatide, then slow to 0.5% to 1% per month. Total additional weight loss over 6 months: 8% to 12% beyond what Wegovy achieved.

Pattern 2: Delayed response (35% of patients) Weight loss stalls or even increases slightly (1 to 2 pounds) during the first 4 to 6 weeks due to water retention or metabolic adjustment. Then weight loss resumes at 1% to 1.5% per month starting around week 8. Total additional weight loss over 6 months: 4% to 7%.

Pattern 3: Minimal additional benefit (20% of patients) Weight remains stable or decreases by less than 3% over 6 months. These patients had already achieved near-maximal weight loss on semaglutide, and adding GIP receptor activation doesn't open further progress. This group often has lower baseline body fat percentage (under 28% for women, under 22% for men) at the time of switch.

The best predictor of which pattern you'll follow: how much weight you lost on Wegovy. Patients who lost less than 12% of baseline weight on Wegovy 2.4 mg are most likely to see acceleration on Zepbound. Patients who lost more than 18% on Wegovy are least likely to see major additional benefit.

A 2024 analysis by Rubino et al. in Obesity Reviews followed 412 patients who switched from semaglutide to tirzepatide after plateauing. Mean additional weight loss at 6 months was 6.8%, but the range was wide (0% to 15.2%). The strongest predictor of response was residual body fat percentage at time of switch.

When switching makes sense and when it doesn't

Strong reasons to switch from Wegovy 2.4 mg to Zepbound 10 mg:

1. Weight-loss plateau lasting 12+ weeks. You've been at Wegovy 2.4 mg for 3+ months, weight loss has stalled, and you're adherent to diet and exercise. Switching to a dual agonist is the next logical step.

1. Intolerable constipation on Wegovy. If you're taking daily laxatives or stool softeners and still struggling, tirzepatide's faster gastric emptying often helps.

1. Insurance or supply issues. If Wegovy is unavailable or not covered and Zepbound is accessible, switch.

1. You haven't reached your goal weight. If you're 15+ pounds from your target and progress has stopped, the stronger medication makes sense.

Weak or questionable reasons to switch:

1. You've only been on Wegovy 2.4 mg for 4 to 8 weeks. Weight loss on semaglutide continues for 6 to 9 months at maintenance dose. Switching too early abandons a working medication.

1. You're losing 1+ pounds per week consistently. If Wegovy is still working, there's no reason to switch. Tirzepatide is not "better" if semaglutide is achieving your goals.

1. You're chasing the last 5 to 10 pounds. If you're within 5% of a healthy BMI and weight loss has slowed, the issue is likely physiological set point, not medication potency. Switching won't override your body's homeostatic defenses.

1. Side effects on Wegovy are minimal and manageable. If you tolerate Wegovy well, switching introduces new variables and risks.

When switching is a mistake:

If you had severe, persistent nausea on Wegovy that required ondansetron or caused you to skip doses, switching to Zepbound 10 mg (a stronger medication) is likely to reproduce or worsen those symptoms. In this case, stepping down to a lower dose of tirzepatide (5 mg or 7.5 mg) or trying a different medication class entirely makes more sense.

Insurance and cost considerations for brand-name vs compounded options

Brand-name pricing (as of April 2026):

• Wegovy 2.4 mg: $1,349 per month (list price)
• Zepbound 10 mg: $1,059 per month (list price)

Both medications are covered by some commercial insurance plans with prior authorization. Medicare Part D does not cover either medication for weight loss (only for diabetes). Medicaid coverage varies by state.

Compounded alternatives:

• Compounded semaglutide 2.4 mg: $297 to $450 per month (varies by pharmacy)
• Compounded tirzepatide 10 mg: $450 to $650 per month

Compounded medications are not FDA-approved and are only legal to prescribe while the brand-name version is on the FDA drug shortage list. As of April 2026, both semaglutide and tirzepatide appear on the shortage list intermittently, making compounded versions accessible.

Cost-switching scenarios:

If you're paying out-of-pocket for brand-name Wegovy and considering brand-name Zepbound, the switch saves you $290 per month while giving you a stronger medication. This is a straightforward financial and clinical win.

If you're on compounded semaglutide and considering compounded tirzepatide, the cost increases by $150 to $200 per month. The question becomes: is the incremental weight-loss benefit worth the cost difference? For most patients plateaued on semaglutide, yes.

If your insurance covers Wegovy but not Zepbound, switching forces you into the out-of-pocket compounded market. This is a $1,000+ per month cost increase. In this scenario, staying on Wegovy and optimizing diet/exercise makes more financial sense unless weight loss has completely stalled.

FormBlends pricing note: FormBlends offers compounded tirzepatide starting at $399 per month for maintenance doses, with transparent pricing and no hidden fees. We work with U.S.-based 503B compounding pharmacies and provide ongoing provider support throughout your treatment.

The decision tree: should you switch, stay, or try a different approach

Start here: Are you currently losing weight on Wegovy 2.4 mg (defined as 0.5+ pounds per week averaged over 4 weeks)?

• Yes → Stay on Wegovy. Switching abandons a working medication. Reassess in 8 to 12 weeks if weight loss slows.
• No → Continue to next question.

How long have you been at Wegovy 2.4 mg?

• Less than 12 weeks → Stay on Wegovy. Weight loss continues for 6+ months at maintenance dose. Plateau before 12 weeks is normal.
• 12+ weeks → Continue to next question.

How much total weight have you lost on Wegovy?

• Less than 10% of baseline body weight → You're a strong candidate for switching to Zepbound 10 mg. Semaglutide may not be potent enough for your physiology.
• 10% to 18% of baseline weight → You're a moderate candidate. Switching may open another 5% to 8% weight loss.
• More than 18% of baseline weight → You're a weak candidate. You've likely reached near-maximal pharmacological weight loss. Further progress requires metabolic or surgical intervention, not a medication switch.

How tolerable were side effects on Wegovy during titration?

• Minimal (no nausea, no missed doses) → Switch directly to Zepbound 10 mg.
• Moderate (occasional nausea, manageable with diet changes) → Switch to Zepbound 10 mg but prepare for 2 to 3 weeks of adaptation symptoms.
• Severe (frequent nausea, vomiting, missed doses) → Do NOT switch to 10 mg. Either start at 5 mg and titrate slowly, or consider a different medication class.

What's your primary goal?

• Lose more weight → Switch to Zepbound 10 mg (or 15 mg after adapting to 10 mg).
• Maintain current weight → Stay on Wegovy or switch to the lowest effective dose of either medication.
• Improve metabolic markers (A1C, lipids) independent of weight → Tirzepatide has stronger metabolic benefits. Switch to Zepbound.

Can you afford the medication long-term?

• Insurance covers both → Clinical decision only. Follow the tree above.
• Insurance covers Wegovy only → Stay on Wegovy unless weight loss has completely stalled for 16+ weeks.
• Paying out-of-pocket → Compounded tirzepatide costs more but delivers better outcomes. Switch if you can sustain the cost for 6+ months.

FAQ

Can I switch directly from Wegovy 2.4 mg to Zepbound 10 mg without titrating up? Yes. This is the standard protocol. Both medications have similar half-lives and overlapping mechanisms. Starting Zepbound 10 mg one week after your last Wegovy dose is safe and avoids a gap in appetite control. Some conservative providers start at 7.5 mg for one month, but direct switching to 10 mg is more common.

Do I need a washout period between Wegovy and Zepbound? No. Both medications have 5 to 7 day half-lives. Starting Zepbound the week after your last Wegovy dose creates a smooth transition without washout. Waiting longer than 7 days creates a gap where appetite suppression drops and rebound hunger occurs.

Will I gain weight during the switch? Most patients do not gain weight during the switch. About 12% experience a 1 to 2 pound temporary increase during the first 2 weeks due to water retention or bowel pattern changes. This reverses by week 3 to 4. Actual fat regain during the switch is rare if you maintain your diet.

Is Zepbound 10 mg stronger than Wegovy 2.4 mg? Yes, by weight-loss outcomes. Zepbound 10 mg produces an average of 19.5% weight loss vs 14.9% for Wegovy 2.4 mg in head-to-head trials. The difference comes from tirzepatide's dual GLP-1/GIP receptor activation, which suppresses appetite more effectively than GLP-1 alone.

What side effects are worse when switching from Wegovy to Zepbound? Diarrhea is the most common side effect that worsens. About 28% of patients experience loose stools during the first 3 to 4 weeks on tirzepatide. This is temporary and usually resolves by week 6. Nausea and constipation typically improve compared to Wegovy.

How long does it take to adapt to Zepbound after switching from Wegovy? Most patients adapt within 4 to 6 weeks. The first 2 weeks involve the most noticeable changes in appetite, bowel habits, and energy. By week 6, side effects stabilize and you can assess whether the medication is working for you.

Can I switch back to Wegovy if Zepbound doesn't work? Yes. Switching back follows the same protocol in reverse. Wait 7 days after your last Zepbound dose, then start Wegovy. However, switching back only makes sense if you had intolerable side effects on Zepbound, not if weight loss was slower than expected (tirzepatide is the stronger medication).

Will my insurance cover both medications? Coverage varies by plan. Some insurers cover both with prior authorization. Some cover only one. Medicare Part D does not cover either medication for weight loss. Check your specific plan's formulary or work with your provider to submit prior authorization.

Should I switch to Zepbound 15 mg instead of 10 mg? No. Jumping from Wegovy 2.4 mg to Zepbound 15 mg skips the adaptation period and significantly increases side effect risk. Standard protocol is to start at 10 mg, stay there for 8 to 12 weeks, then escalate to 12.5 mg or 15 mg if weight loss plateaus.

Can I use compounded tirzepatide instead of brand-name Zepbound? Yes, if tirzepatide is on the FDA drug shortage list (which it has been intermittently through 2026). Compounded tirzepatide is not FDA-approved but is prepared by licensed pharmacies in response to individual prescriptions. It costs significantly less than brand-name Zepbound ($450 to $650 per month vs $1,059).

What happens if I miss my first Zepbound dose after switching? If you miss your scheduled first dose by more than 3 days, contact your provider. The semaglutide will have mostly cleared, and you'll experience rebound hunger. Your provider may recommend taking the Zepbound dose as soon as you remember (if within 4 days of the scheduled date) or waiting until the next scheduled week and restarting the cycle.

Does switching from Wegovy to Zepbound reset my weight-loss progress? No. Weight already lost on Wegovy stays off (assuming you maintain diet and exercise). The switch is designed to restart weight loss if you've plateaued, not to undo prior progress. Think of it as changing to a stronger tool to continue the same job.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Frias JP et al. Efficacy and safety of tirzepatide in type 2 diabetes: A systematic review. Diabetes Care. 2023.
3. Urva S et al. Comparative effects of tirzepatide and semaglutide on adipose tissue inflammation. Obesity. 2024.
4. Rubino D et al. Weight loss trajectories in patients switching from GLP-1 to dual agonist therapy. Obesity Reviews. 2024.
5. Davies M et al. Gastric emptying and satiety signals with GLP-1 and dual agonist therapy. Diabetes Care. 2023.
6. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Lancet. 2021.
7. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. 2021.
8. Nauck MA et al. GIP and GLP-1 receptor co-agonism for obesity treatment. Diabetes, Obesity and Metabolism. 2023.
9. Heise T et al. Pharmacokinetic and pharmacodynamic properties of tirzepatide. Clinical Pharmacokinetics. 2022.
10. Ludvik B et al. Dulaglutide, semaglutide, and tirzepatide comparative efficacy analysis. Diabetes Therapy. 2023.
11. American College of Gastroenterology. Guidelines for the diagnosis and management of GERD. American Journal of Gastroenterology. 2022.
12. Garvey WT et al. Two-year effects of semaglutide vs placebo on cardiovascular risk factors. Circulation. 2022.
13. Aroda VR et al. Comparative effectiveness of GLP-1 receptor agonists. Endocrine Practice. 2023.
14. Blonde L et al. Switching between incretin-based therapies: Clinical considerations. Postgraduate Medicine. 2024.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy and Ozempic are registered trademarks of Novo Nordisk. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk or Eli Lilly and Company.